Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4881350 | 0.98 | NR1H2 (0.54) | NR1H2NR1H3SMN1; SMN2MEN1LMNA | |
| SCHEMBL18893587 | 0.89 | NR1H3 (0.56) | NR1H2NR1H3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25686471 | 0.85 | LMNA (0.47) | NR1H2NR1H3SMN1; SMN2MEN1LMNA | |
| SCHEMBL2080679 | 0.84 | NR1H3 (0.56) | NR1H2NR1H3SMN1; SMN2MLYCDRORC | |
| SCHEMBL8178051 | 0.82 | MEN1 (0.61) | SMN1; SMN2MEN1LMNAHTTKMT2A | |
| SCHEMBL181559 | 0.79 | MAPT (0.52) | LMNA | |
| SCHEMBL11347496 | 0.78 | HDAC3 (0.51) | SMN1; SMN2MEN1LMNAHTTKMT2A | |
| SCHEMBL5953442 | 0.78 | MLYCD (0.50) | NR1H2NR1H3SMN1; SMN2MLYCDRORC | |
| SCHEMBL2077709 | 0.77 | SMN1; SMN2 (0.51) | NR1H2NR1H3SMN1; SMN2MLYCDRORC | |
| SCHEMBL6236337 | 0.77 | MEN1 (0.55) | SMN1; SMN2MEN1LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4267920-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| JP-2004523542-A | — | — | 2004-08-05 | — | — | JP | claimed |
| EP-1377290-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2002064136-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | WO | claimed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2021235392-A1 | ANTI-SARS-COV-2 DURG | オンコリスバイオファーマ株式会社 | 2021-11-25 | — | — | WO | disclosed |
| EP-1917233-B1 | ANILINOHEXAFLUOROISOPROPANOL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1917233-B1 | ANILINOHEXAFLUOROISOPROPANOL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080221176-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080221176-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080221176-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | disclosed |
| WO-2007024954-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024954-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1377290-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1377290-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003090732-A1 | LXR MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002064136-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | NR1H2 278/4885NR1H3 465/4885SMN1; SMN2 4289/4885 |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | NR1H2 1305/4885NR1H3 1471/4885SMN1; SMN2 2729/4885 |
| US-20080221176-A1 | Chemical Compounds | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885SMN1; SMN2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.